




Supplemental Figure S1. Positive correlation of serum acid sphingomyelinase (S-ASM) with liver enzyme activities GGT, ALT, and AST in the total cohort ($n = 229$, a-c) and the subgroup of male ($n = 30$) but not female ($n = 31$) healthy controls (d-f). GGT gamma-glutamyl transferase, ALT alanine aminotransferase (glutamic-pyruvic transaminase, GPT), AST aspartate aminotransferase (glutamic-oxaloacetic transaminase, GOT).

Supplemental table S1. Sex-specific demographic and laboratory data for females corresponding to Table 1 for the whole groups. See legend of Table 1 for details.

Parameters					<i>p</i> values for group difference			
	PU	PM	PR	HC	PU vs. PM	PU vs. HC	PM vs. HC	PR vs. HC
<i>n</i> at inclusion	36	32	31	28				
<i>n</i> at follow-up	34	28						
age (years)	45 (33–53)	46 (32–55.5)	52 (47–63)	47 (32–60)	0.810	0.642	0.645	0.109
total education years ^a	15 (13–17)	14 (12–17)	14 (12–15)	14 (12–17)	0.216	0.527	0.585	0.792
BMI (kg/m ²)	24.0 (21.3–27.3)	27.3 (22.1–30.6)	25.3 (22.7–29.2)	24.3 (23–26.2)	0.055	0.664	0.124	0.309
BDI-II score at inclusion	29 (21–36)	33 (27–39)	3 (0–5)	1 (0–4)	0.176	<0.001	<0.001	0.368
BDI-II score at follow-up ^c	22 (15–27)	24 (16–36)			0.318			
BDI-II score at relative change ^c	−0.23 (−0.42–0.06)	−0.21 (−0.42–0.01)			0.955			
HAM-D score at inclusion	22 (19–26)	24 (21–27)	2 (1–4)	1 (0–3)	0.095	<0.001	<0.001	0.256
HAMD-D score at follow-up ^c	18 (14–21)	17 (11–22)			0.804			
HAMD-D score at relative change ^c	−0.24 (−0.38–0.05)	−0.24 (−0.44–0.08)			0.471			
MADRS score at inclusion	26 (22–28)	28 (25–35)	1 (0–4)	1 (0–2)	0.046	<0.001	<0.001	0.216
MADRS score at follow-up ^c	21 (18–25)	20 (15–29)			0.755			
MADRS score relative change ^c	−0.18 (−0.30–0.04)	−0.18 (−0.46–0.10)			0.258			
STAI state score at inclusion	47 (40–56)	55 (48–66)	32 (30–35)	29 (26–32)	0.009	<0.001	<0.001	0.034
STAI state score at follow-up ^c	46 (36–51)	49 (45–59)			0.047			
STAI state score relative change ^c	−0.05 (−0.15–0.03)	−0.02 (−0.17–0.09)			0.794			
STAI trait score at inclusion	62 (56–68)	65 (53–67)	36 (28–41)	29 (25–35)	0.830	<0.001	<0.001	0.013
STAI trait score at follow-up ^c	58 (52–62)	58 (53–67)			0.666			
STAI trait score relative change ^c	−0.06 (−0.13–0.02)	−0.04 (−0.12–0.07)			0.497			
SF-12 physical component score ^b	49.6 (37.3–56.8)	50.6 (42.3–55.0)	54.3 (49.2–56.7)	56.3 (55.2–57.5)	0.709	0.003	0.001	0.035
SF-12 mental component score ^b	19.4 (16.6–29.9)	16.5 (12.0–26.9)	52.5 (48.1–57.0)	54.3 (50.8–58.2)	0.094	<0.001	<0.001	0.185
CRP (mg/L)	1.0 (0.6–2.3)	1.8 (0.90–3.4)	1.5 (1.0–2.2)	1.4 (0.8–3.3)	0.057	0.074	0.853	0.627
Triglycerides (mg/dL)	75 (57–108)	106 (84–136)	88 (69–139)	80 (64–111)	0.003	0.396	0.039	0.320
Total cholesterol (mg/dL)	211 (185–268)	226 (189–265)	237 (209–263)	217 (185–255)	0.511	0.970	0.449	0.335
HDL cholesterol (mg/dL)	65 (58–71)	59 (51–71)	62 (55–74)	66 (58–73)	0.180	0.720	0.141	0.366
LDL cholesterol (mg/dL)	140 (118–182)	152 (128–190)	154 (136–177)	134 (112–167)	0.258	0.763	0.167	0.154
HDL/LDL ratio	2.1 (1.7–2.8)	2.6 (1.9–3.1)	2.3 (1.9–3.1)	2 (1.7–2.5)	0.117	0.660	0.037	0.120
GGT (U/L)	18 (13–23)	18 (12–26)	18 (13–24)	18 (14–21)	0.863	0.965	0.896	1.000
ALT (U/L)	17 (14–23)	17 (13–24)	17 (14–23)	18 (16–24)	0.975	0.236	0.295	0.429
AST (U/L)	22 (19–25)	22 (19–25)	23 (19–27)	24 (21–27)	0.693	0.038	0.088	0.403
S-ASM (fmol/h/μL serum) at inclusion	138 (119–178)	151 (112–216)	148 (102–196)	177 (130–224)	0.363	0.090	0.573	0.133
S-ASM (fmol/h/μL serum) at follow-up ^c	133 (96–186)	178 (140–245)			0.015			
S-ASM relative change ^c	0.05 (−0.21–0.21)	0.12 (−0.01–0.28)			0.165			

Supplemental table S2. Sex-specific demographic and laboratory data for males corresponding to Table 1 for the whole groups. See legend of Table 1 for details.

Parameters	PU	PM	PR	HC	<i>p</i> values for group difference			
					PU vs. PM	PU vs. HC	PM vs. HC	PR vs. HC
<i>n</i> at inclusion	27	34	30	11				
<i>n</i> at follow-up	27	32						
age (years)	49 (35–53)	46 (33–53)	49 (33–53)	36.5 (30–49)	0.642	0.143	0.244	0.407
total education years ^a	16 (13–19)	14 (13–16)	15 (13–17)	16.5 (14–18)	0.073	0.936	0.028	0.413
BMI (kg/m ²)	25.7 (23.3–28.3)	28.5 (26.7–30.2)	25.8 (25.6–27.0)	25.0 (22.9–28.4)	0.003	0.854	0.003	0.424
BDI-II score at inclusion	28 (23–32)	27 (21–32)	1 (0–3)	2 (0–3)	0.810	<0.001	<0.001	0.851
BDI-II score at follow-up ^c	18 (15–22)	17 (10–27)			0.402			
BDI-II score at relative change ^c	−0.34 (−0.41–−0.15)	−0.36 (−0.56–−0.10)			0.448			
HAM-D score at inclusion	21 (19–23)	22 (20–25)	2 (0–3)	0 (0–1)	0.439	<0.001	<0.001	0.116
HAMD-D score at follow-up ^c	18 (14–20)	13 (9–21)			0.173			
HAMD-D score at relative change ^c	−0.13 (−0.38–−0.05)	−0.38 (−0.58–−0.24)			0.009			
MADRS score at inclusion	27 (24–29)	27 (23–34)	2 (0–2)	0 (0–1)	0.541	<0.001	<0.001	0.080
MADRS score at follow-up ^c	20 (18–24)	17 (13–23)			0.127			
MADRS score relative change ^c	−0.21 (−0.34–−0.09)	−0.34 (−0.49–−0.23)			0.032			
STAI state score at inclusion	52 (46–58)	53 (40–62)	26 (22–36)	27 (25–31)	0.839	<0.001	<0.001	0.965
STAI state score at follow-up ^c	48 (42–54)	45 (39–57)			0.639			
STAI state score relative change ^c	−0.08 (−0.14–0.02)	−0.05 (−0.12–0.07)			0.527			
STAI trait score at inclusion	62 (57–67)	58 (52–67)	31 (25–35)	27 (25–32)	0.085	<0.001	<0.001	0.591
STAI trait score at follow-up ^c	59 (54–64)	56 (50–60)			0.216			
STAI trait score relative change ^c	−0.06 (−0.11–−0.02)	−0.04 (−0.17–0.01)			0.701			
SF-12 physical component score ^b	51.6 (39.1–57.6)	52.2 (45.2–58.4)	56.2 (50.2–56.5)	55.7 (53.8–56.5)	0.529	0.143	0.416	0.835
SF-12 mental component score ^b	20.0 (16.6–26.3)	20.1 (15.4–26.0)	57.2 (50.8–58.9)	56.9 (52.6–58.9)	0.866	<0.001	<0.001	0.788
CRP (mg/L)	0.9 (0.5–2.1)	1.6 (1.1–2.7)	1.0 (0.8–2.4)	1.2 (0.6–1.9)	0.058	0.761	0.044	0.873
Triglycerides (mg/dL)	108 (79–134)	157 (112–191)	101 (65–127)	90 (60–175)	0.003	0.406	0.010	0.919
Total cholesterol (mg/dL)	224 (189–254)	244 (199–272)	211 (196–235)	198 (172–243)	0.299	0.185	0.019	0.828
HDL cholesterol (mg/dL)	52 (46–59)	45 (41–52)	45 (42–53)	51 (47–61)	0.016	0.879	0.030	0.080
LDL cholesterol (mg/dL)	152 (121–179)	173 (138–197)	148 (139–166)	131 (117–169)	0.144	0.123	0.001	0.315
HDL/LDL ratio	2.9 (2.3–3.7)	3.7 (2.8–4.5)	3.2 (2.5–3.7)	2.6 (2.0–3.3)	0.007	0.133	<0.001	0.174
GGT (U/L)	24 (18–43)	39 (23–53)	25 (17–32)	22 (15–33)	0.023	0.263	0.003	0.761
ALT (U/L)	26 (19–36)	33 (27–50)	23 (19–33)	29 (19–33)	0.020	0.955	0.032	0.942
AST (U/L)	25 (21–34)	28 (22–35)	27 (20–37)	30 (23–35)	0.227	0.128	0.471	0.344
S-ASM (fmol/h/μL serum) at inclusion	161 (129–242)	185 (157–240)	158 (90–177)	160 (126–210)	0.504	0.774	0.294	0.359
S-ASM (fmol/h/μL serum) at follow-up ^c	167 (126–223)	193 (159–211)			0.475			
S-ASM relative change ^c	0.00 (−0.17–0.28)	0.04 (−0.14–0.24)			0.704			

Supplemental table S3. Comparison of activities of secretory acid sphingomyelinase (S-ASM) in the serum of patients and controls depending on specific medications. Except for the first three lines, activities and the number of individuals (*n*) is provided for those taking the indicated drug. Mann–Whitney U-test for the comparison of activities with drug versus without drug with nominal $p < 0.05$ in bold. Groups: PU unmedicated depressive patients, PM medicated depressive patients, HC healthy controls, PR patients with remitted major depressive disorder; FIASMA - functional inhibitor of acid sphingomyelinase (less than 50% residual activity in a cell culture model). Please note, that these drugs have been tested at higher concentrations than present in patients' blood. Class refers to the classification of psychotropic substances as indicated in the first lines. Reference: Kornhuber, J.; Tripal, P.; Gulbins, E.; Muehlbacher, M. Functional Inhibitors of Acid Sphingomyelinase (FIASMA) in E. Gulbins and I. Petrache (eds.), Sphingolipids: Basic Science and Drug Development, Handbook of Experimental Pharmacology 215, DOI 10.1007/978-3-7091-1368-4_9, # Springer-Verlag Wien 2013.

Drugs	class	FIASMA	median S-ASM activity (pmol/h/μL)										<i>p</i> values (with vs. without drug)				
			all	<i>n</i>	UP	<i>n</i>	MP	<i>n</i>	RP	<i>n</i>	HC	<i>n</i>	all	UP	MP	RP	HC
all			161.8	229	150.5	63	175.7	66	150.4	39	173.2	61					
no drugs			151.8	101	148.6	41		0	144.8	17	152.4	43					
any drug			175.7	128	150.9	22	175.7	66	154.4	22	202.4	18	0.018	0.594		0.380	0.006
anti-epileptic drug (AED)	1		156.4	10	216.3	2	156.4	6	144.0	2	.	0	0.281		0.969		0.075
antipsychotic	2		173.7	33	219.7	3	170.0	29	177.2	1	.	0	0.291	0.322	0.713	0.183	
benzodiazepine	3		137.8	14	219.7	3	137.7	11	.	0	.	0	0.909		0.655		
monoamine oxidase inhibitor (MAOI)	4		262.8	3	.	0	262.8	3	.	0	.	0	0.649		0.662		
noradrenergic and specific serotonergic antidepressant	5		185.7	23	91.5	1	190.7	22	.	0	.	0	0.698		0.705	0.183	
norepinephrine and dopamine reuptake inhibitor	6		164.5	7	.	0	160.2	6	177.2	1	.	0	0.137		0.305	0.425	
selective serotonin reuptake inhibitor (SSRI)	7		181.9	36	216.3	2	184.1	28	129.5	6	.	0	0.813		0.574	0.656	
serotonin and norepinephrine reuptake inhibitor	8		141.3	18	.	0	141.3	16	138.3	2	.	0	0.269		0.358		
stimulant	9		276.7	1	.	0	276.7	1	.	0	.	0	0.215		0.520	0.374	
tricyclic antidepressant (TCA)	10		137.9	11	.	0	131.3	10	186.0	1	.	0	0.211		0.463	0.790	
different psychotropic drug	11		205.4	12	91.5	1	206.4	11	.	0	.	0	0.452	0.187	0.348		
Acetylsalicylic acid	-	-	254.2	2	223.3	1		0		0	285.1	1	0.081	0.296		0.173	
Aconit pain relieving plant oil	-		187.1	1		0	187.1	1		0		0	0.535		0.694		
Agomelatine	11		187.2	3		0	187.2	3		0		0	0.362		0.569		
Allopurinol	-		207.3	2		0	101.3	1		0	313.3	1	0.780		0.198		0.125
Alprazolam	3		87.0	1	87.0	1		0		0		0	0.151	0.138			
Amiloride	-		224.4	2	135.5	1		0		0	313.3	1	0.493	0.700			0.125
Amisulpride	2		211.6	1		0	211.6	1		0		0	0.364		0.416		
Amitriptyline	10	+	137.7	1		0	137.7	1		0		0	0.586		0.416		
Amlodipine	-	+	313.3	1		0		0		0	313.3	1	0.123				0.120
Aripiprazole	2		114.0	3		0	114.0	3		0		0	0.528		0.380		
Asenapine	2		164.5	1		0	164.5	1		0		0	0.928		0.813		
asthma spray	-		184.8	1		0		0		0	184.8	1	0.576				0.650

Atorvastatin	-		155.8	2	0	101.3	1	210.4	1	0	0.855		0.198	0.248	
Bisoprolol	-		151.3	3	246.2	2		0	103.1	1	0	0.888	0.240	0.424	
Bisphosphonate	-		345.3	1		0		0		0	345.3	1	0.102		0.100
Budesonide	-		151.3	1	151.3	1		0		0		0	0.809	0.956	
Bupopriion	6	-	174.5	7		0	174.1	6	219.2	1	0	0.698		0.705	0.183
Candesartan	-		118.8	5		0	118.8	3	162.6	2	0	0.785		0.678	0.610
Carbamazepine	1	-	174.5	3		0	174.5	3		0	0	0.986		0.747	
Carvedilol	-	+	276.7	1		0	276.7	1		0	0	0.155		0.135	
Cetirizine	-		241.6	2	.	0	241.6	2	.	0	.	0	0.108	0.108	
Citalopram	7	-	162.5	12		0	155.8	9	206.1	3	0	0.785		0.336	0.562
Clomipramine	10	+	118.8	1		0	118.8	1		0	0	0.364		0.331	
Clozapine	2	-	100.0	1		0	100.0	1		0	0	0.232		0.181	
Diazepam	3	-	145.4	1		0	145.4	1		0	0	0.717		0.582	
Duloxetine	8		170.2	8		0	176.9	7	112.8	1	0	0.888		0.763	0.594
Enalapril	-		187.2	3		0	187.2	3		0	0	0.629		0.914	
Escitalopram	7		211.6	9		0	211.6	9		0	0	0.240		0.317	
Ezetimibe	-		61.3	1	61.3	1		0		0	0	0.096	0.099		
Flurazepam	3		211.6	1		0	211.6	1		0	0	0.364		0.416	
Fluticasone/Salmeterol	-	-	101.3	1		0	101.3	1		0	0	0.250		0.198	
Homeopathic drugs	-		205.5	2	205.5	2		0		0	0	0.966	0.969		
Hormonal contraceptive	-		184.5	13	112.5	2	375.9	1	141.0	2	187.7	8	0.626	0.196	0.098
Hydrochlorothiazide	-		165.6	6	188.8	2	157.3	2	112.8	1	313.3	1	0.717	0.583	0.736
Ibuprofen	-	-	104.5	1		0	104.5	1		0	0	0.263		0.217	0.125
Insulin	-		150.5	3	150.5	1	179.6	2	.	0	.	0	0.191	1.000	1.000
Iodine	-		155.4	5	162.8	2	14.1	1	163.3	2		0	0.433	0.666	0.088
Irbesartan	-		313.3	1		0		0		0	313.3	1	0.123		0.125
Lamotrigine	1	-	173.3	4		0	145.4	3	210.4	1	0	0.790		0.633	0.248
Lercanidipine	-	-	153.0	2		0	153.0	2		0	0	0.847		0.708	
Levodopa/benserazide	11		246.2	1		0	246.2	1		0	0	0.244		0.306	
Lisinopril	-		242.1	1	242.1	1		0		0	0	0.257	0.248		
Lithium	11		170.7	6		0	183.0	5	158.4	1	0	0.774		0.913	0.790
Loratadine	-	+	187.8	2	187.8	2		0		0	0	0.676	0.530		
Lorazepam	3		177.4	12	230.9	2	144.4	10	.	0	.	0	0.757	0.126	0.128
Losartan	-		389.2	1	389.2	1		0		0	0	0.090	0.088		
L-Thyroxine	-		180.4	34	147.0	6	183.0	13	194.0	10	223.8	5	0.195	0.623	0.968
Macrogol	-		100.0	1		0	100.0	1		0		0	0.232	0.181	
Magnesium	-		150.4	1		0		0	150.4	1		0	0.785		1.000
Metformin	-		169.0	2		0	118.8	1	219.2	1		0	0.966	0.331	0.183
Metoprolol	-		212.0	2		0	211.6	1	212.5	1		0	0.195	0.416	0.214
Mirtazapine	5	-	176.9	23	.	0	176.9	23	.	0	.	0	0.649	0.662	

Moclobemide	4		128.1	2	0	128.1	2	0	0	0.379	0.246						
Modafinil	9		240.3	1	0	240.3	1	0	0	0.269	0.358						
Nifedipine	-		273.9	1	0	273.9	1	0	0	0.164	0.149						
Nitrendipine	-		183.5	1	0	183.5	1	0	0	0.628	0.854						
Nortriptyline	10	+	165.6	2	0	165.6	2	0	0	0.881	0.881						
Olanzapine	2		164.5	5	0	164.5	5	0	0	0.865	0.490						
Opipramol	10	-	229.8	4	0	273.6	3	186.0	1	0	0.103	0.144	0.374				
Oxcarbazepine	1		196.3	1	0	196.3	1	0	0	0.468	0.582						
Pancreatin	-		225.6	1	0	0	225.6	1	0	0.304		0.155					
Pantoprazol	-		118.8	5	135.3	2	100.0	3	0	0	0.040	0.505	0.030				
Paroxetine	7	+	273.9	1	0	273.9	1	0	0	0.164	0.149						
Pipamperone	2	-	185.4	6	219.7	1	183.5	5	0	0	0.635	0.322	0.837				
Pregabalin	1		196.9	4	0	174.5	3	219.2	1	0	0.311	0.794	0.183				
Propranolol	-	-	163.6	1	0	163.6	1	0	0	0.988	0.733						
Quetiapine	2	-	164.5	11	0	164.5	11	0	0	0.453	0.763						
Ramipril	-		179.0	12	150.3	3	179.0	6	161.1	2	285.1	1	0.232	0.540	0.698	0.702	0.173
Risperidone	2		177.9	6	0	170.0	5	219.2	1	0	0.382	0.990	0.183				
Salbutamol	-		212.5	3	0	187.6	2	212.5	1	0	0.499	0.911	0.214				
Selen	-		155.3	1	0	0	0	0	155.3	1	0.892				0.776		
Sertraline	7	+	184.7	11	0	184.7	9	165.0	2	0	0.218	0.355	0.610				
Simvastatin	-		220.0	2	0	0	0	126.7	1	313.3	1	0.555	0.790	0.125			
Sitagliptin	-		242.1	1	242.1	1	0	0	0	0	0.257	0.248					
St John's wort	11		187.1	1	0	187.1	1	0	0	0.535	0.694						
Statins	-		137.7	1	0	137.7	1	0	0	0.586	0.416						
Sumatriptan	-		164.6	2	164.6	2	0	0	0	0.829	0.811						
Tamoxifen	-	+	264.1	1	0	264.1	1	0	0	0.180	0.198						
Tamsulosin	-		389.2	1	389.2	1	0	0	0	0.090	0.088						
Tianeptine	10		225.9	2	0	225.9	2	0	0	0.154	0.217						
Tranylcypromine	4		227.6	1	0	227.6	1	0	0	0.297	0.386						
Trimipramine	10	+	163.6	1	0	163.6	1	0	0	0.988	0.733						
Urapidil	-		118.8	1	0	118.8	1	0	0	0.364	0.331						
Valproic Acid	1		164.5	1	0	164.5	1	0	0	0.940	0.773						
Valsartan	-		135.7	2	0	101.3	1	0	170.2	1	0.486	0.198	0.955				
Venlafaxine	8	-	184.1	12	0	183.5	11	210.4	1	0	0.677	0.673	0.248				
Vitamine B4	-		73.5	1	0	0	73.5	1	0	0.166	0.131						
Vitamine B6	-		112.0	2	0	0	112.0	2	0	0.972	0.279						
Vitamine D	-		114.8	6	0	91.8	3	139.8	2	213.8	1	0.162	0.024	0.750	0.394		
Zinc	-		105.9	2	61.3	1	0	150.4	1	0	0.170	0.099	1.000				
Ziprasidone	2		174.5	1	0	174.5	1	0	0	0.809	0.979						

Supplemental table S4. Comparison of activities of secretory acid sphingomyelinase (S-ASM) in the serum of patients and controls depending on comorbidities and smoking status. Comorbidities were assessed according to the structured clinical interview for DSM-IV. Groups: PU unmedicated depressive patients, PM medicated depressive patients, HC healthy controls, PR patients with remitted major depressive disorder; Mann–Whitney U-test and Kruskal–Wallis test with nominal $p < 0.05$ in bold. The following categories were completely absent in our cohort: schizophrenia, schizophreniform disorder, substance abuse (alcohol or other drugs), obsessive-compulsive disorder, posttraumatic stress disorder, somatization disorder.

Comorbidities		median S-ASM activity (fmol/h/μL)										p value				
		all	n	PU	n	PM	n	PR	n	HC	n	all	PU	PM	PR	HC
Smoking status	smoker	189.1	56	153.2	16	187.2	23	212.5	7	192.2	10	0.011	0.950	0.163	0.036	0.224
	ex-smoker	155.3	49	143.4	14	146.0	9	111.8	10	176.4	16					
	nonsmoker	153.7	124	150.5	33	165.4	34	151.8	22	152.4	35					
Bipolar I	yes	164.5	11	157.2	4	164.5	7	.	0	.	0	0.978	0.800	0.860		
	no	161.2	218	150.5	59	180.8	59	150.4	39	173.2	61					
Bipolar II	yes	206.1	4	135.5	3	276.7	1	.	0	.	0	0.433	0.897	0.135		
	no	161.8	225	150.9	60	174.5	65	150.4	39	173.2	61					
Panic disorder	yes	151.3	15	151.3	9	153.8	6	.	0	.	0	0.672	0.844	0.365		
	no	163.6	213	150.4	54	180.8	59	150.4	39	173.2	61					
Agoraphobia, social phobia, specific phobia, generalized anxiety disorder	yes	179.3	33	178.3	14	184.7	15	154.3	3	163.7	1	0.066	0.120	0.134	0.685	0.865
	no	155.5	193	148.6	49	170.0	49	144.8	35	173.6	60					

Supplemental table S5. Correlation between S-ASM activity and change of the 20 sub-item scores of the STAI trait inventory between inclusion and follow-up (approximately three weeks) in medicated female depressed patients ($n = 32$, rho and p values from Spearman correlations, nominal $p < 0.05$ in bold).

item #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
reversed	x					x	x			x			x			x			x	
rho	0.474	-0.088	-0.081	-0.073	0.110	0.434	0.575	0.058	0.119	0.497	0.159	0.126	0.409	0.208	0.038	0.540	0.242	0.100	0.450	0.105
p	0.006	0.631	0.658	0.693	0.550	0.013	0.001	0.751	0.515	0.004	0.383	0.493	0.020	0.254	0.837	0.001	0.183	0.587	0.010	0.567